Case Series

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience

Table 1

Summary of cases.

Case #Age/sexPrimary tumor diagnosis (year), treatmentDiagnosis of metastatic uveal melanoma (MUM), siteGenomic findingsMUM treatmentSide effectsResponse to immunotherapy

168, M2013, brachytherapyApril 2016, liver metastasesNo genetic alterationsIpilimumab 3 mg/kg and nivolumab 1 mg/kg for three cycles, followed by nivolumab 240 mg × 2 weeks + monthly TACE until February 2017Autoimmune colitisStable disease
269, M2014, enucleationJune 2016, pulmonary metastasesGNAQ Q209P +veIpilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four cyclesAutoimmune colitisProgression of disease
377, M2014, enucleationMarch 2017, liver and pulmonary metastasesGNA11 Q209L +ve, BAP +ve, MGMT +veIpilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four cycles followed by nivolumab 240 mg every 2 weeks plus monthly TACENoneStable disease
476, F2014, brachytherapyJune 2017, liver metastasesGNA11 Q209L +veIpilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four cycles followed by nivolumab 240 mg every two weeks until November 2017NoneStable August 2017, POD November 2017
565, M2014, enucleationAugust 2016, liver metastasesGNAQ Q209P +ve, MYC +ve, BAP +ve, DNMT3A +ve, low mutational burdenIpilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks followed by nivolumab 240 mg every 2 weeks plus TACE from January 2017NonePartial response
663, M2016, enucleationFebruary 2017, liver metastasesNAIpilimumab 3 mg/kg plus nivolumab 1 mg/kg initiated in May 2017 for two cycles, followed by nivolumab 240 mg every 3 weeks plus TACE from August 2017Autoimmune colitis with combinationPartial response
773, F2015, brachytherapySeptember 2015, liver metastasesNo genetic alterations, c-KIT +veTACE plus Abraxane for three cycles followed by ipilimumab 3 mg/kg plus nivolumab 1 mg/kg for one cycle in February 2017, pembrolizumab 200 mg every 3 weeks from May 2017 to September 2017Autoimmune colitis with combinationProgression of disease
855, M2016, brachytherapyJune 2017, liver metastasesNAMonthly TACE from August 2017, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four cycles followed by nivolumab 240 mg every 2 weeks from December 2017NoneStable disease